(MedPage Today) — SAN DIEGO — Investigational zoldonrasib was well tolerated and showed encouraging clinical activity in previously treated KRAS G12D-mutated non-small cell lung cancer (NSCLC), according to a phase I study.
Among patients…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.






